Ken Griffin Portage Biotech Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Portage Biotech Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 22,886 shares of PRTG stock, worth $4,806. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,886
Previous 14,139
61.86%
Holding current value
$4,806
Previous $25,000
52.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PRTG
# of Institutions
27Shares Held
2.16MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY1.67MShares$349,8350.01% of portfolio
-
Bison Wealth, LLC213KShares$44,8130.02% of portfolio
-
Peak6 Investments LLC Chicago, IL55.3KShares$11,6050.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny32.8KShares$6,8930.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny31.7KShares$6,6490.0% of portfolio
About PORTAGE BIOTECH INC.
- Ticker PRTG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,943,700
- Market Cap $3.56M
- Description
- Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a smal...